Chronic restlessness with antipsychotics

American Journal of Psychiatry

Volumn 164, Issue 11, 2007, Pages 1648-1654

  Bratti, Irene M ^a   Kane, John M ^b   Marder, Stephen R ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROPRANOLOL; RISPERIDONE;

ACUTE DISEASE; ADULT; AKATHISIA; CASE REPORT; CLINICAL ASSESSMENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MALE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PSYCHOMOTOR AGITATION; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 36749015768     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.07071150     Document Type: Review

References (58)

1. Barnes TR: The Barnes Akathisia Rating Scale - revisited. J Psychopharmacol 2003; 17:365-370
2. Haskovec L: Akathisie. Bohemes Med Clin 1902; 17:704-708
3. Barnes TR, Braude WM: Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42:874-878
4. Sachdev P: Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale, and proposal. Psychopharmacology (Berl) 1994; 114:181-186
5. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S: Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4:157-175
6. Sachdev P: Akathisia and Restless Legs. New York, Cambridge University Press, 1995
7. Sachdev P: The epidemiology of drug-induced akathisia, I: acute akathisia. Schizophr Bull 1995; 21:431-449
8. Sachdev P: The epidemiology of drug-induced akathisia, II: chronic, tardive, and withdrawal akathisias. Schizophr Bull 1995; 21:451-461
9. Mattay VS, Casey DE: Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia, in Schizophrenia. Edited by Hirsch SR, Weinberger DR. Blackwell Scientific Science, 2003, pp 552-572
10. Sachdev PS, Brune M: Animal models of acute drug-induced akathisia: a review. Neurosci Biobehav Rev 2000; 24:269-277
11. Adler LA, Angrist B, Reiter S, Rotrosen J: Neuroleptic-induced akathisia: a review. Psychopharmacology (Berl) 1989; 97:1-11
12. Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175:1054-1060
13. Rodnitzky RL: Drug-induced movement disorders. Clin Neuropharmacol 2002; 25:142-152
14. Miller CH, Fleischhacker WW: Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000; 22:73-81
15. Kushida CA: Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. Am J Med 2007; 120(suppl 1): S4-S12
16. Hirose S: The causes of underdiagnosing akathisia. Schizophr Bull 2003; 29:547-558
17. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
18. Ekbom KA: Restless legs. JAMA 1946; 131:481-486
19. Hening WA: Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007; 120(suppl 1):S22-S27
20. Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974; 30:13-19
21. Van Putten T: Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1975; 31:67-72
22. Gualtieri CT: The problem of tardive akathisia. Brain Cogn 1993; 23:102-109
23. Haase JH: Uber Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen-bzw Largactil-Dauerbehandlung (Occurrence and interpretation of psychomotor parkinsonism in megaphen or largactil prolonged therapy). Der Nervenarzi 1954; 25:486-492
24. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
25. Rifkin A, Quitkin F, Klein DF: Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 1975; 32:672-674
26. Van Putten T: The many faces of akathisia. Compr Psychiatry 1975; 16:43-47
27. Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35:51-68
28. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
30. Marder SR: Lessons from each drug trial (editorial). Am J Psychiatry 2007; 164:375-376
31. Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233-246
32. Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R: A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63:516-523
33. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003; 160:1405-1412
34. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
35. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB (Sertindole Study Group): Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782-791
36. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM: An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003; 64:898-906
37. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer MM (HGDH Study Group): Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160:1396-1404
38. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B: A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2:345-349
39. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425
40. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR: The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002; 28:5-16
41. Lima AR, Bacaltchuk J, Barnes TR, Soares-Weiser K: Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2004; 4: CD001946
42. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR: Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2002; 1:CD001950
43. Rathbone J, Soares-Weiser K: Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006; 4: CD003727
44. Parlak I, Erdur B, Parlak M, Ergin A, Ayrik C, Tomruk O, Turkcuer I, Ergin N: Midazolam vs diphenhydramine for the treatment of metoclopramide- induced akathisia: a randomized controlled trial. Acad Emerg Med 2007; 14:715-721
45. Dorevitch A, Durst R, Ginath Y: Propranolol in the treatment of akathisia caused by antipsychotic drugs. South Med J 1991; 84: 1505-1506
46. Duncan EJ, Adler LA, Stephanides M, Sanfilipo M, Angrist B: Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol 2000; 23:169-173
47. Hermesh H, Manor I, Munitz H: Propranolol: a treatment for pseudoakathisia. J Nerv Ment Dis 1994; 182:241-243
48. Kim A, Adler L, Angrist B, Rotrosen J: Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1989; 9:294-296
49. Lipinski JF, Zubenko GS, Barreira P, Cohen BM: Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983; 2:685-686
50. Lipinski JF Jr, Zubenko GS, Cohen BM, Barreira PJ: Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984; 141:412-415
51. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A: Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia: a randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006; 59:1071-1077
52. Ratey JJ, Salzman C: Recognizing and managing akathisia. Hosp Community Psychiatry 1984; 35:975-977
53. Vinson DR, Drotts DL: Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 2001; 37:125-131
54. Wells BG, Cold JA, Marken PA, Brown CS, Chu CC, Johnson RP, Nasdahl CS, Ayubi MA, Knott DH, Arheart KL: A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. J Clin Psychiatry 1991; 52:255-260
55. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A: Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58:318-322
56. Peacock L, Solgaard T, Lublin H, Gerlach J: Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996; 124:188-196
57. Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J: The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994; 55:142-145
58. Levin H, Chengappa KN, Kambhampati RK, Mahdavi N, Ganguli R: Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53:248-251